NPH Insulin Onset and Peak Activity
NPH insulin becomes active approximately 1-2 hours after subcutaneous injection, with peak action occurring 4-6 hours post-injection, and a total duration of action lasting up to 24 hours.
Pharmacokinetic Profile
Based on the most recent FDA drug labeling and clinical guidelines, NPH (Neutral Protamine Hagedorn) insulin demonstrates the following time-action characteristics 1:
- Onset of action: Approximately 30 minutes to 1 hour after injection
- Peak effect: 4-6 hours after administration 2, 3, 4
- Duration of action: Up to 24 hours
The FDA labeling for Novolin 70/30 (which contains 70% NPH) specifically states that effects begin approximately ½ hour after injection, with maximal effect between 2 and approximately 12 hours 1.
Clinical Application Context
Glucocorticoid-Induced Hyperglycemia
The 4-6 hour peak action of NPH makes it ideally suited for managing steroid-induced hyperglycemia. When patients receive intermediate-acting glucocorticoids like prednisone (which reach peak plasma levels in 4-6 hours), NPH should be administered concomitantly with the steroid dose to match the timing of peak hyperglycemic effect 2, 3, 4.
Enteral Nutrition Coverage
For patients on continuous enteral nutrition, NPH can be given every 8-12 hours to provide intermediate-acting coverage 3, 4.
Important Clinical Caveats
Individual variability is substantial. The time course of NPH action may vary considerably between different individuals and even at different times in the same individual 1. This variability stems from:
- Differences in subcutaneous absorption
- Injection site selection (abdominal injection may result in faster absorption)
- Need for proper resuspension before injection (NPH contains a cloudy suspension that must be mixed thoroughly)
The prolonged duration of NPH action increases hypoglycemia risk, particularly during overnight periods and between meals, compared to newer long-acting basal insulin analogs 5, 6. This is why modern guidelines generally favor basal insulin analogs (glargine, detemir, degludec) over NPH for routine basal insulin coverage in most patients with type 1 diabetes 5.
However, NPH remains clinically useful and cost-effective in specific situations, particularly for matching the pharmacodynamic profile of intermediate-acting glucocorticoids 2, 3, 4.